Explore the Future of Health Care Innovation
Are you seeking groundbreaking startups to invest in? Join Mike Partsch and Greg Keenan at the JPM Annual Healthcare Conference this January to explore some of the cutting-edge companies in the WARF Ventures portfolio.
| Atrility Medical | AyrFlo | Elucent Medical | ||
| Immuto Scientific | Madison Scientific | PROMISS Dx |
Atrility Medical uses its proprietary database of cardiac waveforms, captured through its patented monitoring device, to develop software and AI models to predict and prevent cardiac events—delivering more accurate insights for clinicians in the ICU, across the hospital and into remote care settings. By enhancing both the speed and accuracy of arrhythmia detection, Atrility’s technology helps improve patient outcomes, reduce hospital stays and lower health care costs.
CEO: Sean McCormick
AyrFlo is developing a continuous, wearable and wireless breathing monitoring sensor for post-surgical patients to detect respiratory deterioration early and prevent respiratory failure after high risk surgery. Post-surgical breathing complications increase the length of stay significantly, increasing treatment cost, loss of finite beds and loss of revenue due to missed additional surgeries. AyrFlo’s monitoring sensor will lead to safer recovery and faster discharge while opening up finite hospital beds for additional surgeries.
CEO: Guelay Bilen-Rosas
Guiding You with Precision—Every Step of the Way
At Elucent Medical, we’re reshaping surgical guidance with tools designed to make surgery less invasive, more precise, and profoundly efficient. Our technology, built on the principles of In-Body Spatial Intelligence™ (iSi), provides you with real-time data on depth, distance, and direction, creating a seamless experience where precision is effortless. This true 3D surgical awareness sets us apart, giving you an unprecedented view into each step of the procedure and minimizing uncertainties.
President & CEO: Jason Pesterfield
Immuto Scientific is redefining the landscape of target discovery by revealing the structural fingerprints of disease. Through its therapeutic discovery arm, Immuto is discovering and developing first-in-class therapeutics that target structural changes in cell-surface proteins unique to disease. Powered by its AI-enabled target discovery and epitope-identification platforms, Immuto discovers novel, targetable surface protein conformations (SPCs) from patient-derived samples, driving the development of safer, more precise therapies. With its disease-agnostic platform, Immuto is building a differentiated pipeline with an initial focus on oncology.
CEO: Faraz Choudhury
Madison Scientific (MadSci) is a neurotech company developing novel devices for the treatment and monitoring of patients with hydrocephalus and other neurologic conditions. Their SmartShunt™ Hydrocephalus Management System includes an implantable device that integrates a proprietary valve with advanced sensor technology to continuously monitor and regulate intracranial pressure. The system aims to reduce diagnostic uncertainty and the high failure and complication rates associated with existing shunt technology, representing a paradigm shift that has the potential to improve long-term outcomes and quality of life for a growing patient population.
CEO: Tyler Wanke
PROMISS Diagnostics has developed an innovative, AI-driven clinical diagnostic tool that applies machine-learning–based risk assessment to diagnose ovarian cancer at early stage. Leveraging routinely collected biomarkers and patient data, the test aims to shorten diagnostic timelines and reduce unnecessary surgeries by enabling detection at earlier, more treatable stages. A clearly defined FDA 510(k) pathway using retrospective data, combined with existing CPT reimbursement, supports rapid clinical adoption and capital-efficient commercialization in a large, underserved women’s health market.
CEO: Jalal Sulaiman